SCHEMBL1558078

SCHEMBL1558078

O=c1[nH]cc(C=C(Br)Br)c(=O)[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPYD Q12882 5/20 0.59
GAA P10253 2/20 0.48
MAPT P10636 3/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 2/20 0.43
ATAD2 Q6PL18 1/20 0.43
CYP19A1 P11511 1/20 0.43
TSHR P16473 1/20 0.43
THPO P40225 1/20 0.43
MTOR P42345 1/20 0.43
HTT P42858 1/20 0.43
HBB P68871 1/20 0.43
PMP22 Q01453 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4C Q9H3R0 2/20 0.35
POLB P06746 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4A O75164 1/20 0.35
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1052480 0.86 DPYD (0.53) DPYDGAAMAPTALDH1A1LMNA
SCHEMBL10696940 0.76 DPYD (0.65) DPYDGAAMAPTALDH1A1LMNA
SCHEMBL65892 0.75 DPYD (0.62) DPYDGAAMAPTALDH1A1LMNA
SCHEMBL1228163 0.74 DPYD (0.63) DPYDGAAMAPTALDH1A1LMNA
SCHEMBL170251 0.74 DPYD (1.00) DPYDGAAMAPTALDH1A1LMNA
SCHEMBL7822163 0.73 DPYD (0.57) DPYDGAAMAPTALDH1A1LMNA
SCHEMBL4497888 0.72 DPYD (0.46) DPYDGAAMAPTALDH1A1LMNA
SCHEMBL190328 0.72 DPYD (0.59) DPYDGAAMAPTALDH1A1LMNA
SCHEMBL190329 0.72 DPYD (0.59) DPYDGAAMAPTALDH1A1LMNA
SCHEMBL8966741 0.71 DPYD (0.59) DPYDGAAMAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181199-B2 Uracil derivatives and use thereof RESPROTECT GMBH (DE) 2015-11-10 US disclosed
US-20110166096-A1 URACIL DERIVATIVES AND USE THEREOF RESPROTECT GMBH (DE) 2011-07-07 US disclosed
EP-2303848-A2 URACIL DERIVATIVES AND USE THEREOF Resprotect GmbH (DE) 2011-04-06 EP disclosed
WO-2009156182-A2 URACIL DERIVATIVES AND USE THEREOF RESPROTECT GMBH (DE) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166096-A1 URACIL DERIVATIVES AND USE THEREOF TYMP, UNG, DPYD DPYD 3/4885GAA 2007/4885MAPT 4246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.